## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.2% below STRENGTH zone (3.0-6.0%); PEG 33.66 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.78)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Wall Street Analysts Have Consensus Hold Recommendation For Baxter International Inc. (BAX)**
- Source: Finviz | 20251209T055300 | Neutral | Relevance: 99%
- Wall Street analysts have a consensus "Hold" rating for Baxter International Inc. (BAX), with a one-year average share price target of $23.80, representing a 28% upside potential. This comes after Morgan Stanley cut its price target to $15 with an "Underweight" rating, and Argus Research downgraded the stock due to a significant dividend reduction planned for January 2026, aimed at strengthening the balance sheet. Despite favorable trends in medical technology, BAX has seen a 36% year-to-date slump.

**2. Pomerantz LLP Notifies Shareholders of Lawsuit Filed Against Baxter International, Inc. â€“ BAX**
- Source: FOX40 News | 20251211T000815 | Neutral | Relevance: 99%
-  Pomerantz LLP has announced a class action lawsuit against Baxter International, Inc. (NYSE: BAX) concerning potential securities fraud. The lawsuit stems from Baxter's decision to temporarily halt shipments of its Novum LVP medical device, which caused a significant drop in its stock price. Shareholders who purchased Baxter securities during the Class Period have until December 15, 2025, to seek appointment as Lead Plaintiff.

**3. Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity**
- Source: Business Wire | 20251211T133153 | Bullish | Relevance: 99%
- Baxter International Inc. presented real-world data at the American Society of Health-System Pharmacists meeting, showcasing that smart infusion pump integration with EMR systems significantly enhances patient safety and nursing efficiency. The analysis, conducted in collaboration with The University of Texas Medical Branch, involved over a million infusions and demonstrated reductions in patient safety alerts and time spent on programming and alert resolution. These findings highlight the potential of connected infusion therapy to reduce medication errors, alleviate clinician burnout, and improve overall compliance.

**4. Investors who lost money on Baxter International, Inc.(BAX) should contact Levi & Korsinsky about pending Class Action - BAX**
- Source: WJBF | 20251209T090000 | Neutral | Relevance: 99%
-  Levi & Korsinsky, LLP has announced a class action securities lawsuit against Baxter International, Inc. (NYSE: BAX) on behalf of investors who suffered losses due to alleged securities fraud between February 23, 2022, and July 30, 2025. The lawsuit claims Baxter made false statements and concealed systemic defects in its Novum LVP product, leading to malfunctions and patient risks. Investors have until December 15, 2025, to request to be appointed as lead plaintiff.

**5. Baxter International, Inc. (BAX) Investors: December 15, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser**
- Source: FOX40 News | 20251209T130800 | Neutral | Relevance: 99%
-  Lieff Cabraser Heimann & Bernstein, LLP encourages investors of Baxter International, Inc. (NYSE:BAX) who purchased stock between February 23, 2022, and October 29, 2025, to contact them regarding a securities class action. The lawsuit alleges that Baxter made misleading statements and failed to disclose critical defects with its Novum LVP device, leading to significant stock price drops following reports of malfunctions, an FDA recall, and a halt in shipments. The deadline to apply as lead plaintiff is December 15, 2025.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 33.7x requires aggressive growth execution.
2. Elevated short interest (9.7%): bears positioning against stock.
3. Long-term trend broken: trading 29.1% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 33.66 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.7B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 9.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 33.66 |
| Forward P/E | 8.2 |
| Current P/E | 8.0 |
| YoY Growth | -2.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.3% to 1.2% (+3.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.8pp (needs >3.0% for momentum thesis). MRS_5 at 2.7% confirms short-term momentum alignment. Outperforming sector by 3.5pp, stock-specific strength. Below SMA200 (0.71x), long-term trend not supportive. RSI neutral at 50.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.16% (CS: 50) | Neutral |
| RSI_14 | 49.6 | Neutral |
| MACD Histogram | 0.15 | Bullish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 0.937x | Below |
| vs SMA200 | 0.709x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.90
- **Stop Loss:** $17.78 (5.9% risk)
- **Target:** $20.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1232
- **Position Value:** $23,284.80
- **Portfolio %:** 23.28%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*